Liftstream is an executive search recruitment company in the life sciences sector
Dimension Therapeutics Diversifies Leadership with Management and Board Appointment
Dimension Therapeutics, a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders has announced that it has expanded its Board of Directors with the elections of Georges Gemayel, Ph.D., former Executive Vice President of Genzyme Corporation, and Arlene M. Morris, former CEO of Syndax Pharmaceuticals. Dimension also announced that Donald J. Hayden, Jr., is leaving his position as a member of the Company’s Board of Directors.
M&A Continues to Dominate the Rare Diseases Landscape
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.
13 Life Science Leaders to watch in 2013 – The Verdict!
Authored by Liftstream
NPS Pharma submits BLA for Natpara
Authored by James Sheppard
Onyx deal signals broader interest in orphan drugs
Authored by Karl Simpson
Sangart awaits key clinical data in 2013
Authored by James Sheppard
NPS Pharmaceuticals gets ready to launch gastro orphan drug
Authored by Karl Simpson